2 results match your criteria: "Department of Medicine at the University of California in San Francisco[Affiliation]"
New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection.
Gastroenterol Hepatol (N Y)
June 2017
Dr Peters is a professor of medicine and chief of hepatology research in the Department of Medicine at the University of California in San Francisco, California. Dr Locarnini is a professor of microbiology and immunology at the University of Melbourne and is director of the WHO Regional Reference Laboratory for Hepatitis B within the Victorian Infectious Diseases Reference Laboratory at the Doherty Institute in Melbourne, Australia.
Chronic hepatitis B (CHB) affects over 350 million individuals worldwide and is the most common cause of liver cancer. In the United States, CHB affects at least 2 to 3 million individuals, and current therapies can control the disease but not cure it. There are over 30 new molecules being studied in CHB in preclinical to phase 2 studies, targeting specific parts of the hepatitis B virus (HBV) life cycle and the host immune response.
View Article and Find Full Text PDFParasites and T helper cell development: some insights.
Parasitol Today
December 1994
Department of Medicine at the University of California in San Francisco, CA 94143, USA.
Five years after the initial observations implicating the T helper (Th)-cell dichotomy (Th1/Th2) as the focal point in the immunoregulation of murine infection with Leishmania major, investigation has shifted to the factors that govern the differentiation of a specific immune response from its pre-immune of undifferentiated state. In this article, Steven Reiner focuses on the most recent advances concerning the lineage commitment of mature Th-cell populations, showing how new techniques [such as polymerase chain reaction (PCR) and transgenic mice] have allowed for a more-careful dissection of the early evolution of an immune response.
View Article and Find Full Text PDF